Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
AstraZeneca Pharma India | The Organization has Obtained import and market Consent in form CT-20 (Following new drug approval) from the Drugs Controller General of India for Osimertinib 40mg/80mg film coated tablets (TagrissoTM). The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets into a new disease area in India. AstraZeneca said on Tuesday it has agreed to provide up to half a million additional doses of its experimental antibody-based COVID-19 combination remedy to the United States for $205 million.
In October, the Anglo-Swedish drugmaker and U.S. government agencies had originally agreed for a supply of 200,000 doses. The expansion brings possible U.S. supplies of the treatment to 700,000 US doses and the total value of the deal to $726 million.
The treatment, AZD7442, is a mixture of two monoclonal antibodies and hasn’t been approved for use as yet, AstraZeneca said, adding that the new agreement is contingent on an approval from the U.S. Food and Drug Administration.
The company said it doesn’t expect any changes to its own 2021 predictions due to the deal.
